Zobrazeno 1 - 4
of 4
pro vyhledávání: '"James D. Warner"'
Autor:
Tomomi Sakai, Nan Yan, James D. Warner, Brock G. Bennion, Cathrine A. Miner, Jianjun Wu, Teresa L. Ai, Ricardo A. Irizarry-Caro, Derek J. Platt, Jonathan J. Miner, Amber M. Smith, Vijay K. Gonugunta
Publikováno v:
The Journal of Experimental Medicine
Warner et al. show that knock-in mice expressing a human disease–associated STING mutation spontaneously develop inflammatory lung and skin disease, hypercytokinemia, and T cell cytopenia, which occurs independently of IRF3.
Patients with stim
Patients with stim
Autor:
Jason W. Alsup, Michael I. Jesson, Jamie L. Lee, Craig J. Thomas, Richard D. Head, Martin E. Dowty, Zaher A. Radi, Scott M. Steward-Tharp, Kamran Ghoreschi, John J. O'Shea, Masao Tanaka, Debra M. Meyer, Timothy P. LaBranche, Chad E. Storer, Massimo Gadina, Xiong Li, James D. Warner, Sarbani Ghosh, Nandini Kishore, John C. Minnerly
Publikováno v:
The Journal of Immunology. 186:4234-4243
Inhibitors of the JAK family of nonreceptor tyrosine kinases have demonstrated clinical efficacy in rheumatoid arthritis and other inflammatory disorders; however, the precise mechanisms by which JAK inhibition improves inflammatory immune responses
Autor:
Shashi K. Ramaiah, Christie L. Funckes-Shippy, Nandini Kishore, Xiong Li, James D. Warner, Jeffrey L. Hirsch, Michael I. Jesson, Dale L. Morris, Debra M. Meyer, Matthew J. Saabye, Mollisa M. Elrick, Cindy J. Gross, Jennifer L Barks, Martin E. Dowty
Publikováno v:
Journal of Inflammation, Vol 7, Iss 1, p 41 (2010)
Journal of Inflammation (London, England)
Journal of Inflammation (London, England)
Background The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors. CP-690,550 is a potent and selective JAK inhibitor currently in clinical tri
Autor:
Jaime L. Masferrer, James K. Gierse, Karen Seibert, Kathleen M. Leahy, Jeffery S. Carter, Yan Zhang, Luz A. Cortes-Burgos, James D. Warner, Maureen A. Nickols
Publikováno v:
European journal of pharmacology. 588(1)
A new class of selective cyclooxygenase-2 (COX-2) inhibitors has been identified by high throughput screening. Structurally distinct from previously described selective COX-2 inhibitors, these benzopyrans contain a carboxylic acid function and CF3 fu